ArticleBMC microbiology2026
Three-year cumulative antibiogram of breast-associated secretion and drainage specimens in female patients in Syria (2022-2024): microbiologic spectrum, antimicrobial susceptibility, and annual MSSA trends.
Article in BMC microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Microbiological Spectrum and Antimicrobial Susceptibility Patterns of Culture-Positive Thoracic and Respiratory Specimens in Syria: A Retrospective Laboratory-Based Study.International journal of microbiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBreast discharge and breast abscesses are common clinical presentations with heterogeneous etiologies. When infection is suspected, culture with antimicrobial susceptibility testing (AST) is essential to guide targeted therapy, particularly in settings where antimicrobial resistance and antibiotic misuse may influence empirical choices. We aimed to characterize the microbiologic spectrum and cumulative susceptibility patterns of breast-associated secretion and drainage specimens submitted for culture in a private central microbiology laboratory in Damascus, Syria, and to assess annual MSSA susceptibility trends.
methodsWe performed a retrospective, laboratory-based analysis of breast-associated secretion and drainage specimens from female patients processed between 1 January 2022 and 31 December 2024. To minimize duplicate-sampling bias, only the first culture per patient per calendar year was included, and annual cohorts represented unique patients. Organisms were categorized as Gram-positive or Gram-negative. Susceptibility was summarized as S/I/R with explicit reporting of numbers tested per antibiotic. An annual MSSA trend analysis across 2022–2024 was conducted for selected clinically relevant agents using Pearson’s chi-square test.
resultsWe included 122 cultures (2022: 42; 2023: 35; 2024: 45; mean age 37.4 years). Gram-positive organisms predominated (74.6%). All Staphylococcus aureus isolates were phenotypically methicillin susceptible by direct MIC-based testing, making MSSA the most common isolate (84/122, 68.9%), followed by E. coli (14/122, 11.5%). MSSA showed universal susceptibility to methicillin and vancomycin and high susceptibility to linezolid, with lower susceptibility to fluoroquinolones, TMP-SMX, and fusidic acid. E. coli and pooled Enterobacterales showed highest activity to carbapenems and amikacin, with variable fluoroquinolone activity and low cephalosporin activity. These Gram-negative findings should be interpreted cautiously because of the small organism-specific and pooled denominators. MSSA minocycline susceptibility increased significantly over time (Pearson’s chi-square test, p = 0.006); other agents showed no significant annual change.
conclusionThis three-year cumulative antibiogram provides locally relevant susceptibility data for breast-associated secretion and drainage specimens submitted for culture in Syria, supporting context-specific empiric therapy, culture-guided refinement, early de-escalation, and stewardship, with careful interpretation of low-denominator estimates.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.